Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Sarepta Therapeutics, Inc. - Common Stock (NQ:SRPT)

16.47 -0.33 (-1.96%)

Streaming Delayed Price Updated: 10:19 AM EDT, May 26, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	523,602
Open	16.89
Bid (Size)	16.47 (400)
Ask (Size)	16.48 (200)
Prev. Close	16.80
Today's Range	16.47 - 17.00
52wk Range	10.41 - 43.92
Shares Outstanding	93,148,652
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

My Top 3 Biotech Stocks for May 2026 ↗

May 20, 2026

As FDA activity accelerates and big pharma searches for its next generation of blockbuster drugs, select biotech companies are beginning to stand out from the crowd.

Via The Motley Fool

Sarepta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference

May 13, 2026

From Sarepta Therapeutics, Inc.

Via Business Wire

Performance

YTD	-22.7%	-22.7%
1 Month	-21.5%	-21.5%
3 Month	-9.1%	-9.1%
6 Month	-12.9%	-12.9%
1 Year	-57.1%	-57.1%

More News

Sarepta (SRPT) Q1 2026 Earnings Transcript ↗

May 06, 2026

Via The Motley Fool

Sarepta Therapeutics (NASDAQ:SRPT) Q1 2026 Earnings Beat Overshadowed by Revenue Dip ↗

May 06, 2026

Via Chartmill

Sarepta Therapeutics Announces First Quarter 2026 Financial Results and Recent Corporate Developments

May 06, 2026

From Sarepta Therapeutics, Inc.

Via Business Wire

Sarepta Therapeutics to Announce First Quarter 2026 Financial Results

April 22, 2026

From Sarepta Therapeutics, Inc.

Via Business Wire

BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in BioMedWire Editorial Highlighting Biotech’s Shift Toward Science-Driven Asset Valuation

April 20, 2026

Via Investor Brand Network

When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in Biotech

April 20, 2026

Via Investor Brand Network

When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in Biotech

April 20, 2026

From BioMedWire

Via GlobeNewswire

Ultragenyx Vaults Toward Commercialization as FDA Accepts Landmark Gene Therapy BLA

April 02, 2026

Via MarketMinute

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 31, 2026

From Sarepta Therapeutics, Inc.

Via Business Wire

Biotech Defies Gravity: Sarepta and Corcept Lead Midday Healthcare Rally Amidst Market Volatility

March 31, 2026

Via MarketMinute

Sarepta's RNA Renaissance: 35% Surge as siRNA Breakthrough Silences Skeptics

March 26, 2026

Via MarketMinute

Sarepta Therapeutics (SRPT) Stock Surges 34.98% on Breakthrough Clinical Data

March 26, 2026

Via MarketMinute

The RNA Renaissance: Decoding Sarepta Therapeutics’ 34% Surge and the Future of Precision Medicine

March 26, 2026

Via Finterra

Let's have a look at the top gainers and losers one hour before the close of the markets of today's session. ↗

March 25, 2026

Via Chartmill

Wednesday's session: top gainers and losers ↗

March 25, 2026

Via Chartmill

Which stocks are gapping on Wednesday? ↗

March 25, 2026

Via Chartmill

Sarepta Therapeutics (SRPT) at a Crossroads: A 2026 Deep Dive into the Future of Genetic Medicine

March 25, 2026

Via Finterra

Sarepta Announces First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1

March 25, 2026

From Sarepta Therapeutics, Inc.

Via Business Wire

Sarepta to Share First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1

March 24, 2026

From Sarepta Therapeutics, Inc.

Via Business Wire

2 Beaten-Down Stocks That Still Aren't Worth Buying ↗

March 21, 2026

Via The Motley Fool

Sarepta Provides Regulatory Update on AMONDYS 45® and VYONDYS 53®

March 19, 2026

From Sarepta Therapeutics, Inc.

Via Business Wire

Sarepta Shares Rise As Company Begins Enrollment In Gene Therapy Safety Enhancement Study ↗

March 16, 2026

Via Stocktwits

Sarepta Announces that Screening and Enrollment are Underway in ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with Duchenne

March 16, 2026

From Sarepta Therapeutics, Inc.

Via Business Wire

Frequently Asked Questions

Is Sarepta Therapeutics, Inc. - Common Stock publicly traded?

Yes, Sarepta Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does Sarepta Therapeutics, Inc. - Common Stock trade on?

Sarepta Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Sarepta Therapeutics, Inc. - Common Stock?

The ticker symbol for Sarepta Therapeutics, Inc. - Common Stock is SRPT on the Nasdaq Stock Market

What is the current price of Sarepta Therapeutics, Inc. - Common Stock?

The current price of Sarepta Therapeutics, Inc. - Common Stock is 16.47

When was Sarepta Therapeutics, Inc. - Common Stock last traded?

The last trade of Sarepta Therapeutics, Inc. - Common Stock was at 05/26/26 10:19 AM ET

What is the market capitalization of Sarepta Therapeutics, Inc. - Common Stock?

The market capitalization of Sarepta Therapeutics, Inc. - Common Stock is 1.53B

How many shares of Sarepta Therapeutics, Inc. - Common Stock are outstanding?

Sarepta Therapeutics, Inc. - Common Stock has 2B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.